A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T Portfolio News / By Karina Tin May 16, 2024 A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T Read More »
(Carmot) Roche Reports Positive Phase Ib Results For Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity Portfolio News / By Karina Tin May 16, 2024 (Carmot) Roche Reports Positive Phase Ib Results For Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity Read More »
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Portfolio News / By Karina Tin May 14, 2024 Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Read More »
RAPT Therapeutics Reports First Quarter 2024 Financial Results Portfolio News / By Karina Tin May 9, 2024 RAPT Therapeutics Reports First Quarter 2024 Financial Results Read More »
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates Portfolio News / By Karina Tin May 6, 2024 ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates Read More »
Remix Therapeutics™ Announces First Patients Dosed in Two Phase 1 Clinical Trials Investigating REM-422 for Treatment of Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) Portfolio News / By Karina Tin May 2, 2024 Remix Therapeutics™ Announces First Patients Dosed in Two Phase 1 Clinical Trials Investigating REM-422 for Treatment of Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) Read More »
Cajal Neuroscience and Creyon Bio Announce Partnership to Develop Oligonucleotide-Based Medicines for Neurodegenerative Diseases Portfolio News / By Karina Tin May 1, 2024 Cajal Neuroscience and Creyon Bio Announce Partnership to Develop Oligonucleotide-Based Medicines for Neurodegenerative Diseases Read More »
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Portfolio News / By Karina Tin April 16, 2024 Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Read More »
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC Portfolio News / By Karina Tin April 15, 2024 ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC Read More »
Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting Portfolio News / By Karina Tin April 15, 2024 Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting Read More »
